Screener

Eligibility screening

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (…

Sponsored by Loxo Oncology, Inc.Study detailsClinicalTrials.gov

19 US sites in CA, FL, LA, MD +7

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.